Biomedicine Daily · Friday, 9 October 2026
CBA FRONTIER INSIGHTS
FDA Approves Atezolizumab Plus Chemotherapy for Stage III Mismatch Repair Deficient Colon Cancer
The FDA on October 8 approved atezolizumab (Tecentriq, Genentech) with a fluoropyrimidine and oxaliplatin for adjuvant treatment of Stage III mismatch repair deficient colon cancer in patients two years and older, with the subcutaneous Tecentriq Hybreza form cleared for those 12 and older weighing at least 40 kg. In the ATOMIC trial of 711 adults and one pediatric patient, the combination halved the risk of disease-free survival events versus mFOLFOX6 alone, with a hazard ratio of 0.50, and median DFS was not reached in either arm. Reviews continue at partner agencies under Project Orbis. Elsewhere, a randomized trial in the Journal of Clinical Oncology showed the diabetes drug sitagliptin cut acute graft-versus-host disease risk after alternative-donor stem cell transplantation by half, and argenx stopped the Phase 3 UNITY trial of Vyvgart Hytrulo in Sjogren's disease on futility, sending shares down nearly 14% to around $797.
Clinical readouts and safety
Sitagliptin Halves Acute GVHD Risk After Stem Cell Transplant in Randomized Trial
Sitagliptin, a diabetes drug, cut the risk of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation by half, according to a randomized controlled trial led by the First Affiliated Hospital of Soochow University and published in the Journal of Clinical Oncology. It is described as the first large trial of sitagliptin for aGVHD prevention in transplants from alternative donors.
Argenx shutters Sjogren's study, losing blockbuster expansion opportunity for Vyvgart
Argenx halted the Phase 3 UNITY trial of Vyvgart Hytrulo in Sjogren's disease after an independent data committee found it would not meet its primary endpoint of improving systemic disease activity; the futility analysis covered more than 500 of 630 enrolled patients. Shares fell nearly 14%, to around $797. Separately, argenx reported a Phase 2 celiac disease win for FB102, a CD122 inhibitor acquired for $2.2 billion, meeting its primary endpoint of change in a small-intestine health measure.
[Articles] Oral deucrictibant for on-demand treatment of hereditary angioedema attacks: a phase 3, multicentre, randomised, double-blind, placebo-controlled crossover trial
Oral deucrictibant shortened the time to symptom relief of hereditary angioedema attacks compared with placebo in a phase 3 multicentre, randomised, double-blind, placebo-controlled crossover trial, and was generally well tolerated. The findings support deucrictibant as potentially the first orally administered bradykinin B2 receptor antagonist for treating attacks of bradykinin-mediated angioedema.
medicalxpress.comIntranasal sufentanil-ketamine appears safe, effective for pediatric acute pain
A fixed-dose intranasal sufentanil-ketamine formulation relieved moderate-to-severe acute pain in emergency department patients aged 1 to under 18 years. In the phase 2/3 study of 152 patients, 88% had a pain intensity score of 4 or lower at 30 minutes and 95.4% achieved at least a 30% pain reduction, with no severe adverse events and median sedation scores of 0 or 1. Median treatment satisfaction was 5 out of 5, with 92% acceptability.
medicalxpress.comTwo medications demonstrated comparable results in treating compulsive sexual behavior disorder
Naltrexone and fluoxetine produced no statistically significant difference in symptoms of compulsive sexual behavior disorder after eight weeks in a randomized trial of 80 individuals at Karolinska University Hospital. Symptoms fell in both groups, but naltrexone brought an early reduction while fluoxetine improvements emerged later. Side effects were mostly mild to moderate; nausea was more common with naltrexone and two fluoxetine participants stopped due to severe effects.
Newron reveals 5 deaths in late-stage schizophrenia program as FDA maintains hold
Four deaths have occurred among patients receiving Newron's evenamide across all clinical studies, a 0.56% incidence, versus one death on placebo (0.27%); investigators deem three unrelated and one possibly related. The FDA's hold on the Phase 3 ENIGMA-TRS 2 trial in adjunctive schizophrenia therapy remains in place over concerns that evenamide, a selective voltage-gated sodium channel blocker, may cause irregular heartbeats. Newron reports no pattern of cardiac abnormalities in more than 5,000 ECGs from over 700 patients and is weighing added cardiac screening.
Regulatory and policy
FDA approves atezolizumab in combination with chemotherapy for Stage III mismatch repair deficient colon cancer
The FDA approved atezolizumab (Tecentriq, Genentech) in combination with a fluoropyrimidine and oxaliplatin on October 8, 2026, for adjuvant treatment of Stage III mismatch repair deficient colon cancer in patients two years of age and older, with the subcutaneous Tecentriq Hybreza approved for those 12 years and older weighing 40 kg or greater. In the ATOMIC trial of 711 adults and one pediatric patient, the hazard ratio for disease-free survival was 0.50 versus mFOLFOX6 alone, and median DFS was not reached in either arm. Reviews are ongoing at partner agencies under Project Orbis.
FDA Approves Novartis Remibrutinib for Symptomatic Dermographism in Adults
The FDA has approved Novartis' Rhapsido (remibrutinib) for adults with symptomatic dermographism whose symptoms are not adequately controlled by H1 antihistamines. The decision on October 7, 2026, follows the drug's September 2025 approval in chronic spontaneous urticaria, making Rhapsido the only prescription medicine approved for both of the most common chronic urticaria types.
AstraZeneca's Datroway Approved in China for Metastatic Triple-Negative Breast Cancer Untreatable with PD-1/PD-L1 Inhibitors
AstraZeneca's TROP2-targeted antibody-drug conjugate Datroway (dedatopotamab) has been approved in China for unresectable or metastatic triple-negative breast cancer in patients not suitable for PD-1/PD-L1 inhibitor treatment. In the phase III TROPION-Breast02 study, the drug extended median overall survival by 5 months versus chemotherapy chosen by investigators (hazard ratio = 0.79; 95% confidence interval: 0.64-0.98; p=0.0291), reaching a median OS of nearly two years. It is described as the first and only TROP2 ADC approved for this indication with an OS benefit, and Datroway now has two approved breast cancer indications in China.
gov.ukMHRA approves catumaxomab to treat cancer-related fluid build-up in the abdomen
Trump administration investigates 9 universities for alleged visa fraud
Vice President JD Vance announced that the Department of Labor is investigating Harvard, Yale, Stanford, Brown, Caltech, Arizona State, MIT, the University of Pittsburgh and UC Davis for alleged misuse of J-1 visas, which most international postdocs hold. Inspector General Anthony D'Esposito said subpoenas have already been issued to the schools. The probe's scope and timeline are unclear; related proposed restrictions, including a $100,000 H1-B fee, face lawsuits.
medicalxpress.comNHS labs fail to share data vital for diagnosis and care of rare diseases, investigation finds
A BMJ investigation finds that three of England's seven NHS Genomics Laboratory Hubs, those covering South East, South West, and North East and Yorkshire, are not routinely submitting genetic variants to public databases such as ClinVar, as required since 2024 under ACGS guidance. Even hubs that submit face significant backlogs. The labs cite staffing, technology and infrastructure gaps and say they plan routine submissions this year, while experts warn rare disease patients are missing out on diagnosis and care.
Clinical trial applications advice pilot becomes permanent
The EMA's Accelerating Clinical Trials in the EU (ACT EU) advice pilot, which gives sponsors consolidated pre-submission feedback from Member States on clinical trial applications via CTIS, will become permanent from January 2027. The procedure is coordinated by the Heads of Medicines Agencies through its Clinical Trials Coordination Group. A final report covering roughly 30 pilot applications is due before the end of 2026, with updated guidance and templates published in January 2027.
Industry and deals
Sanofi and Novartis each commit around $8 billion to autoimmune deals
On October 1, Sanofi struck a deal with Regeneron worth up to $8 billion in total potential value. A day later, Novartis committed nearly $7.8 billion to an early-stage pipeline asset from Abogen Biosciences, in the same autoimmune field. The two back-to-back deals show large-scale business development shifting from oncology toward autoimmune disease.
Big Pharma–backed Matchpoint scores $150M series B, advancing autoimmune asset
Preclinical Matchpoint Therapeutics has raised a $150 million series B co-led by Nextech Invest and Norwest, with participation from Sanofi Ventures, Atlas Venture, Access Biotechnology and the T1D Fund. The money will advance MPT-062, an oral T cell modulator for autoimmune and inflammatory conditions, into human trials starting next year. Matchpoint also has a July 2025 deal with Novartis, which paid $60 million upfront for its ACE platform and could owe up to $1 billion in milestones plus royalties.
Viatris boosts pain drug portfolio with $1.7B buyout of Pacira
Viatris is buying Pacira BioSciences for $1.65 billion, paying $36.50 per share in cash, a 45% premium, to gain the non-opioid pain drugs Exparel and Zilretta for post-surgical and osteoarthritis knee pain. Pacira's two main products booked $692 million in sales in 2025, up about 4% from 2024. The deal is expected to close by the end of 2026, with generics for Exparel likely from early 2030 and Zilretta patents expiring in 2031.
STAT+: Roche inks drug discovery deal with Chinese biotech, focused on molecular glue medicines
Roche has signed a discovery collaboration with Chinese startup Defand Therapeutics to develop molecular glue medicines for cancer and immune-driven diseases. Financial terms were not disclosed, but a source said the deal could be worth close to $1 billion in upfront fees and milestone payments tied to preclinical, clinical and regulatory goals. Defand will discover and develop multiple drugs under the partnership.
Research papers
Golgi-derived vesicles containing PI(3,4)P2 drive mitochondrial fusion
Immunoregulatory gene GIMAP6 suppresses lethal atherosclerotic vasculopathy and ischemic heart failure
Loss of the immunoregulatory gene GIMAP6 drives atherosclerosis and ischemic heart disease by destabilizing the endothelium and promoting macrophage lipid loading and inflammation. The mechanism operates without hyperlipidemia, though hyperlipidemia significantly worsens disease progression. The work identifies GIMAP6 as a suppressor of lethal atherosclerotic vasculopathy and ischemic heart failure, adding a lipid-independent route to disease.
Ribosome remodeling drives translation adaptation during viral infection and cellular stress.
Ribosome composition is not fixed but is reprogrammed during cellular stress and viral infection. Infection of human cells by non-segmented negative-sense viruses recruits the large-subunit protein rpL40 to a non-canonical site on the small subunit of 80S ribosomes near the mRNA entry site, and these specialized ribosomes preferentially bind viral mRNAs to enhance viral protein synthesis needed for replication. The same remodeling pathway exists endogenously, where metabolic stress alters ribosome structure to promote translation required for cell survival.
The human gut microbiome primes fever after vaccination
Epigenetic aging and transposon dysregulation reflect size-related lifespan compression in dogs
SLC39-driven zinc influx orchestrates pleiotropic tumor-immune system cross-talk to establish immune suppression in colorectal cancer.
A zinc-CDX2-CD24-SIGLEC10 axis drives immune suppression in colorectal cancer, according to multi-omics analysis of 258 patients integrated with single-cell transcriptomics, spatial profiling and functional assays. SLC39-mediated zinc influx induced tumor cell CD24 expression, which reduced macrophage-mediated engulfment; CD24 blockade restored phagocytosis. A seven-gene signature predicted immunotherapy responses across five colorectal cancer cohorts.
Spatial omics resolves adrenergic and mesenchymal cell states in neuroblastoma
A spatial-omics analysis across 54 neuroblastoma tumors, combining six spatial platforms with single-cell and single-nucleus RNA sequencing, identifies malignant mesenchymal (MES) tumor cells using signatures from patient-derived xenografts. A higher MES score predicts worse patient outcome, resolving a debate over whether MES cells are malignant. It gives neuroblastoma research a cell-state marker tied to prognosis.
medicalxpress.comLow-risk prostate tumors reveal molecular signs linked to more aggressive cancer
A multi-omics machine learning signature identifies molecular features of aggressive prostate cancer in a subset of patients classified as clinically low risk, published in npj Digital Medicine by researchers at KTH Royal Institute of Technology. The approach integrates genomic, transcriptomic and epigenomic data with network analysis to reveal tumor biology that conventional risk classification misses. The method remains at the research stage, with laboratory tests planned to probe therapeutic vulnerabilities it suggests.
Mechanistic insights into chromatin modulation by the “orphan” remodeler ATRX
The structure of the ATRX ATPase-nucleosome complex reveals three distinctive features that enable this orphan remodeler to remodel nucleosomes. These features are indispensable for protecting cells from G4 stress. The structure also provides a framework for interpreting known and future mutations linked to ATRX-related disorders.
Methods and resources
Zhou Xin Team Designs GTAC Bifunctional Molecules to Degrade GPCR Targets via Reprogrammed Trafficking
A team led by Zhou Xin reports in Nature a bifunctional molecule design, GTAC, that drives targeted degradation of G protein-coupled receptors. One end of GTAC binds the target GPCR while the other binds transferrin receptor 1, a rapidly internalizing receptor, reprogramming GPCR trafficking so the receptor is removed rather than merely blocked. The approach aims to overcome the limits of classical antagonists, which require continuous receptor occupation.
How to build a mouse: embryo development captured in stunning detail
Two independent teams used CRISPR-based 'cell recorders' with prime editing to trace mouse embryo development. Jay Shendure's team applied a technique called DNA Typewriter, adding sequential genetic marks as cells divided in a fertilized mouse egg, then reconstructed the relationships of 1.3 million edited cells, about 10% of the embryo's total, after two weeks of development. The approach extends lineage mapping, previously achieved only in C. elegans with its invariant 959 somatic cells, to a mammal.
Bitopic Inhibitor Design Principles Tackle Kinase Resistance and Off-Target Risk at Once
Kevan Shokat's team reports in Nature a kinase inhibitor strategy in which one molecule binds two distinct sites on the same kinase at once, rather than optimizing binding at the ATP pocket alone. Because the ATP-binding pocket is highly conserved across kinase families, higher potency there tends to raise off-target risk, and resistance mutations can erase the advantage of a single-site binder. The work sets out design principles for bitopic inhibitors that address resistance and off-target activity together.
A fluctuation test for gastruloid heterogeneity
Gastruloid variability is largely inherited, not induced, according to a fluctuation test adapted to gastruloids grown from single stem cells. The variability traces back to fluctuations in the state of the founding cell. This reframes a longstanding obstacle for organoids grown under identical conditions as a problem of founding-cell state rather than culture conditions.
AI Agents Build scBaseCount, the Largest Standardized Single-Cell Database with Over 502 Million Cells
scBaseCount, published in Cell by researchers from the Arc Institute, the University of California, Stanford University and others, is the largest public single-cell RNA sequencing database built to date. AI agents mined all public 10x Genomics datasets in the Sequence Read Archive, automatically annotated metadata and reprocessed counts under a uniform standard, covering 27 species, 75 tissues and more than 502 million cells. The resource supplies high-quality, large-scale data for training AI models of cell state and for cross-study integration.
Asymmetric enzymatic hydrophosphorylation through O2 activation
[Articles] Conversational diagnostic artificial intelligence in ambulatory primary care: a prospective feasibility study
A prospective feasibility study in ambulatory primary care tested conversational diagnostic artificial intelligence in a real-world setting. The assessment covered conversation safety and quality, and user acceptance, and found initial feasibility of the AI system. The work is presented as a step toward clinical translation, with further research still needed.
Opinion and commentary
[Correspondence] Bundibugyo virus: coordinating a cross-border response
The Democratic Republic of the Congo and Uganda declared Ebola outbreaks caused by Bundibugyo virus on May 15, 2026, and the WHO Director-General declared a Public Health Emergency of International Concern on May 17, 2026. By Aug 26, 2026, 5815 confirmed cases and 2788 deaths had been reported, with 5794 cases and 2786 deaths in the Democratic Republic of the Congo across 60 health zones in six provinces. The correspondence addresses coordination of the cross-border response.
Plague scare: what scientists know, and what Russia won’t say
A 28-year-old researcher died at the Anti-Plague Research Institute in Irkutsk, Siberia, possibly from pneumonic plague, with news reports saying about 200 people may have been exposed and quarantined. Russia's public-health regulator says there was no emergency and that she died of pneumonia of unknown origin, revealing only on 7 October that she had been vaccinated and that thousands of tests found no dangerous pathogens. The WHO and the US government are demanding epidemiological data; biosecurity specialist Gregory Koblentz says the wider-outbreak risk is minimal but the lack of transparency exposes gaps in global biosurveillance.
Also today
24 events that did not make today's daily, one table per category, one row per event. Open a category to expand.
RegulatoryNMPA Approves GeneScience's Six · FDA Approves Pfizer's TUKYSA Plus Trastuzumab and Pertuzumab for First · Junengen's TIL Therapy Nuojilunsai Injection Proposed for CDE Priority Review in Metastatic Melanoma · telisotuzumab adizutecan …7 ▾▴
Filings, acceptances, designations, approvals and withdrawals at a regulator.
- NMPA Approves GeneScience's SixUpdateChangchun GeneScience Pharmaceutical received NMPA approval, dated 29 September, for its 5.1-class leuprolide mesylate injection (6M), a 42mg ready-to-use in-situ gel depot given subcutaneously every 24 weeks, for prostate cancer requiring androgen deprivation therapy. In a US Phase 3 trial of 137 patients, the 6-monthly 42mg dose achieved a 97% castration rate (testosterone at or below 50ng/dL) at day 28 and through days 28 to 336; a Chinese bridging study at 43 sites in 142 patients showed a 97.9% cumulative probability of maintaining castrate testosterone levels. The product will compete with Livzon's three-month microsphere formulation.NMPA
- FDA Approves Pfizer's TUKYSA Plus Trastuzumab and Pertuzumab for FirstUpdateThe FDA approved Pfizer's TUKYSA (tucatinib) combined with trastuzumab and pertuzumab as maintenance therapy after induction treatment for adults with unresectable locally advanced or metastatic HER2-positive breast cancer. The approval extends TUKYSA into the first-line setting and offers a chemotherapy-free maintenance option. According to Pfizer, the regimen reduced the risk of death by 35.9% compared with trastuzumab alone.FDA
- Junengen's TIL Therapy Nuojilunsai Injection Proposed for CDE Priority Review in Metastatic MelanomaUpdateChina's CDE has proposed priority review for Nuojilunsai Injection, a tumor-infiltrating lymphocyte therapy developed by Junengen, for patients with unresectable or metastatic melanoma who failed at least two prior systemic therapies including a PD-1 antibody. It is described as the first domestic TIL therapy to reach this stage. The priority review designation now moves the application forward in CDE's review process.
- telisotuzumab adizutecanUpdateAbbVie said on October 7, 2026 that the FDA granted two breakthrough therapy designations to telisotuzumab adizutecan (Temab-A; ABBV-400), its c-Met antibody-drug conjugate. One covers the drug with bevacizumab in adults with refractory metastatic colorectal cancer previously treated with fluoropyrimidines, irinotecan, oxaliplatin, anti-VEGF and, where applicable, anti-EGFR monoclonal antibodies; the other covers it alone in locally advanced or metastatic EGFR wild-type, c-Met protein-expressing non-squamous NSCLC after platinum chemotherapy and anti-PD-(L)1 treatment. Both designations rest on results from the first-in-human study M21-404 (NCT05029882).FDA
- NMPA Approves Haihe's Oral Paclitaxel Solution for Recurrent or Metastatic HER2UpdateChina's NMPA approved an oral paclitaxel solution (Bairuisu) from Shanghai Haihe Pharmaceutical for recurrent or metastatic HER2-negative breast cancer, according to its latest drug approval documents. The clearance was among a batch of marketing application approvals listed in the same notice. The article notes that paclitaxel is one of the most widely used chemotherapy drugs and that market demand for it is large.NMPA
- Shengzhi Runhe Gains First Domestic Class III Certificate for Injectable dECM ProductUpdateOn September 21, 2026, Shengzhi Runhe's first partnered product in dECM hydrogel medical aesthetics received a Class III medical device registration certificate (registration number 20263131980) from the National Medical Products Administration, and the company holds full commercial rights to it. Beijing Dikang Medical Investment Management registered a drug master file for extracellular matrix collagen, providing a legally sourced raw material for ECM product development and production in the pharmaceutical industry.NMPA
- FDA says its safety review of abortion pill will continue into next yearUpdateThe FDA told a federal court that its safety review of mifepristone, the nation's main abortion pill, will continue into next year, with a safety study due by mid-December and a report no later than March 2027 before any decision on new restrictions. The reevaluation was ordered by Health Secretary Robert F. Kennedy Jr., and the update came in a case brought by Louisiana over mail delivery of the drug. The Supreme Court has blocked changes to mifepristone until it sees the case again.FDA
ClinicalRetatrutide · Optogenetic Therapy for Restoring Aspects of Visual Function · petrelintide · LAIV …8 ▾▴
Trial starts, early and mid-stage data, and results that did not make the daily.
- RetatrutideUpdateRetatrutide, a first-in-class triple-target hormone receptor agonist, produced clinically meaningful weight loss and improved glycemic control over 80 weeks in adults with obesity or overweight and type 2 diabetes in the TRIUMPH-2 trial, with additional benefits on multiple cardiovascular risk factors. Data were presented at the 62nd EASD meeting in Milan and published in The Lancet.
- Optogenetic Therapy for Restoring Aspects of Visual FunctionUpdate
- petrelintideUpdate
- LAIVUpdate
- Inhaled Treprostinil for Idiopathic Pulmonary FibrosisUpdate
- MimiVax’s cancer vaccine fails phase 2 glioblastoma study, but CEO still sees data as ‘inspiring’Update
- Atsena’s Lighthouse gene therapy readout illuminates eye disease efficacyUpdate
- Cadrenal launches strategic review for lateUpdate
Deals and financingNovartis Licenses Abogen's ABO2203 in RNA Therapy Deal Worth Over $7.775 Billion · Forbion · Enveda · Caribou Biosciences …7 ▾▴
Licensing, M&A and financing that did not make the daily.
- Novartis Licenses Abogen's ABO2203 in RNA Therapy Deal Worth Over $7.775 BillionUpdateAi Bo Biological (Abogen Biosciences) has signed a licensing and option agreement with Novartis to advance RNA therapies. Novartis receives a global exclusive license to Abogen's lead pipeline candidate ABO2203 and options to exclusive licenses on further programs from Abogen's proprietary RNA platform, including mRNA-TCE work. Abogen will receive an upfront payment of $575 million, with the total deal value exceeding $7.775 billion.
- ForbionUpdateDutch life science venture capital firm Forbion closed a new fund at €2.3 billion (about $2.6 billion) on October 6, its largest raise to date and one of the biggest life science VC funds globally in the past five years. The amount exceeded the original target and will be deployed through Forbion Growth Opportunities Fund IV and Forbion Ventures Fund VIII, expected to back around 30 promising biotech companies. The raise follows a marked cooling in the biotech sector in recent years.
- EnvedaUpdateClinical-stage biotechnology company Enveda closed a $311 million Series E financing announced on September 23, 2026. The company uses machine learning combined with metabolomics to identify new compounds. The round follows earlier raises of $150 million in Series D and $130 million in Series C funding.
- Caribou BiosciencesUpdateCaribou Biosciences, the CRISPR company co-founded by Jennifer Doudna, will stop developing its two off-the-shelf cell therapy programs for blood malignancies, citing a financing environment that CEO Rachel Haurwitz called increasingly challenging. The board has cleared management to evaluate a merger, acquisition or other transactions, with Wedbush Securities as exclusive financial advisor. Caribou ended the second quarter with $114 million in cash and securities, and Leerink analyst Daina Graybosch sees a reverse merger or a sale to Tang Capital as likely outcomes.
- UltragenyxUpdate
- Sanofi and Regeneron Expand Antibody Alliance to Develop Four LongUpdateOn October 1, Sanofi and Regeneron announced an expansion of their antibody alliance, which has run for more than twenty years. The expanded collaboration covers four new long-acting antibody drugs targeting type 2 inflammation-related diseases, with the partners jointly developing next-generation long-acting immunology medicines.
- CatalentUpdate
OtherRobitussin Honey CF Max · FDA Pediatric Safety Communications2 ▾▴
Everything else with a concrete event that did not make the daily.
- Robitussin Honey CF MaxUpdateFDA
- FDA Pediatric Safety CommunicationsUpdateFDA